Peer Reviewed Published Studies
Quality of Life Assessment 2007-2010
The purpose of this study was to evaluate quality of life outcomes in patients treated with sublingual immunotherapy at Allergy Associates of La Crosse following the La Crosse Method™ Protocol.
51 patients diagnosed with allergic rhinitis demonstrated by positive skin tests completed the Rhinitis Quality of Life Questionnaire (RQLQ) at their first appointment prior to sublingual immunotherapy treatment and two subsequent appointments, with the average length of treatment during the study being 11.19 months.
Significant improvement (p<0.05) on six of seven categories of the RQLQ questionnaire was noted.
Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.
Total RQLQ Scores Pre-sublingual Immunotherapy and at Subsequent Visits
Survey respondents averaged 1.9 chronic conditions in addition to their allergic rhinitis diagnosis. Chronic conditions included urticaria, food allergies, IBS, asthma, atopic dermatitis, sinusitis, conjunctivitis, chronic fatigue syndrome, thyroiditis, headaches/migraines, contact dermatitis, otitis media, and MCS.
Participants on average were being treated for 15 environmental allergens.
2009 Study on Allergen-Specific Sublingual Immunotherapy in the Treatment of Migraines
One study performed at Allergy Associates of La Crosse revealed that La Crosse Method Protocol sublingual immunotherapy can help alleviate migraines associated with allergies. Of seven patients who completed the study, their quality of life results as well as their migraine self-assessments improved over a year of being on sublingual immunotherapy for allergic rhinitis.
The MIDAS tool was used, an assessment score used to evaluate migraine severity by evaluating days of impaired function at work, school, or other/leisure activities.
MIDAS scores which originally varied from 8-41 (mean = 21.1) improved for all seven patients and their range fell to 0-37 (mean = 9.5). For six subjects the MIDAS range declined to 0-9.
Migraine Disability Assessment Score (MIDAS)
